Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 10236
Country/Region: Zambia
Year: 2015
Main Partner: University Teaching Hospital - Zambia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $8,505,801 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $500,000
Care: Orphans and Vulnerable Children (HKID) $250,000
Care: TB/HIV (HVTB) $500,000
Care: Pediatric Care and Support (PDCS) $1,600,000
Laboratory Infrastructure (HLAB) $808,743
Strategic Information (HVSI) $25,000
Testing: HIV Testing and Counseling (HVCT) $509,308
Sexual Prevention: Other Sexual Prevention (HVOP) $412,750
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $850,000
Treatment: Adult Treatment (HTXS) $2,300,000
Treatment: Pediatric Treatment (PDTX) $750,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 2,389
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,700
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,700
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,450
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 250
PMTCT_ARV Sum of New and Current disaggregates 2016 2,700
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 1,421
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 412
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 1,833
PMTCT_EID Sum of Infant Age disaggregates 2016 1,833
PMTCT_STAT By: Known positives at entry 2016 7,177
PMTCT_STAT By: Number of new positives identified 2016 250
PMTCT_STAT Number of new ANC and L&D clients 2016 15,986
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 15,986
PMTCT_STAT Sum of Positives Status disaggregates 2016 7,427
TX_CURR Age/Sex: <1 Female 2016 40
TX_CURR Age/Sex: <1 Male 2016 39
TX_CURR Age/Sex: 1-4 Female 2016 454
TX_CURR Age/Sex: 1-4 Male 2016 455
TX_CURR Age/Sex: 5-14 Female 2016 715
TX_CURR Age/Sex: 5-14 Male 2016 715
TX_CURR Aggregated Age/Sex: <1 Female 2016 40
TX_CURR Aggregated Age/Sex: <1 Male 2016 39
TX_CURR Aggregated Age/Sex: 15+ Female 2016 8,215
TX_CURR Aggregated Age/Sex: 15+ Male 2016 8,216
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 18,849
TX_CURR Sum of age/sex disaggregates 2016 18,849
TX_CURR Sum of Aggregated Age/Sex (<1 and 1-14) <15 2016 2,418
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 16,431
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 16,431